Sulforaphane and Prostate Cancer - the role of Non-Coding RNA

New biomarkers have been identified that may help in the early diagnosis and treatment of prostate and urological cancers.  Long non-coding RNA (Ribonucleic Acid), a form of RNA not involved in cellular protein encoding, are altered in these cancers.(1,2)

Expression of long non-coding RNA is believed to play a significant role in the initiation and progression of prostate cancer. Sulforaphane has been found to inhibit the expression of  non-coding RNA associated with prostate cancer. Researchers conclude that sulforaphane may prevent and suppress prostate cancer by the inhibition of key non-coding forms of RNA. (3)


 XGEVITY (contains Glucoraphanin - Sulforaphane precursor)

AIR VITALITY (contains Glucoraphanin - Sulforaphane precursor)




(1)  Martens-Uzunova ES, et al. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014 Jun;

(2) Mouraviev B, et al. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar.

(3) Beaver LM, et al. Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer. J Nutr Biochem 2017 Apr;

Gail Paige
Gail Paige